<SEC-DOCUMENT>0001840199-24-000020.txt : 20240325
<SEC-HEADER>0001840199-24-000020.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325170017
ACCESSION NUMBER:		0001840199-24-000020
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240321
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Waldencast plc
		CENTRAL INDEX KEY:			0001840199
		STANDARD INDUSTRIAL CLASSIFICATION:	PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40207
		FILM NUMBER:		24780006

	BUSINESS ADDRESS:	
		STREET 1:		10 BANK STREET, SUITE 560
		CITY:			WHITE PLAINS
		STATE:			NY
		ZIP:			10606
		BUSINESS PHONE:		(917) 546-6828

	MAIL ADDRESS:	
		STREET 1:		10 BANK STREET, SUITE 560
		CITY:			WHITE PLAINS
		STATE:			NY
		ZIP:			10606

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Waldencast Acquisition Corp.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>wald_6-kxnasdaqcomplianced.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8315596ceb614de78b41c9d8055b0f82_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 6-K</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-16 or 15d-16</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:10pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the Month of&#58; March 2024</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Commission File Number&#58; 001-40207</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Waldencast plc</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Translation of Registrant&#8217;s name into English)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">10 Bank Street, Suite 560</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">White Plains, New York, 10606</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Address of principal executive office)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F&#58;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Form 20-F            </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Form 40-F</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9744;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9744;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i8315596ceb614de78b41c9d8055b0f82_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Waldencast Regains Compliance with Nasdaq Filing Requirements </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 21, 2024, Waldencast plc (the &#8220;Company&#8221;) received formal notice from the Nasdaq Hearings Panel (the &#8220;Panel&#8221;) confirming that the Company has regained compliance with Nasdaq&#8217;s filing requirements, as set forth in Nasdaq Listing Rule 5250(c) (the &#8220;Periodic Filing Rule&#8221;) following the filing of the Company&#8217;s financial results for the interim period ended June 30, 2023 with the U.S. Securities and Exchange Commission.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In line with the applicable Nasdaq Listing Rules in such circumstances, the notice also indicated that Nasdaq had imposed a &#8220;Mandatory Panel Monitor&#8221; as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the compliance determination (March 21, 2024), pursuant to which in the event the Company fails to timely satisfy the Periodic Filing Rule during the one-year monitor period, the Company will not have the opportunity to provide a compliance plan for the Nasdaq Listing Qualifications Staff&#8217;s review&#59; rather, Nasdaq would instead issue a delist determination pursuant to which the Company could request a hearing and stay of the delist determination pending another hearing before the Panel. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Waldencast is proud to have accomplished this significant milestone and looks forward to providing further updates on its fiscal year 2023 performance in connection with the publication of its 2023 20-F.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 25, 2024, the Company issued a press release announcing the Panel&#8217;s listing confirmation. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Statements in this report that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include&#58; the Company&#8217;s timing of filing its 2023 20-F&#59; and any assumptions underlying any of the foregoing. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; and &#8220;will&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements, including, among others&#58; (i) the inability to recognize the anticipated benefits of the business combination with Obagi Skincare and Milk Makeup, (ii) failure by the Company to maintain compliance with Nasdaq&#8217;s Periodic Filing Rule , including during the one-year Nasdaq monitoring period, which may result in the Company&#8217;s securities being delisted from Nasdaq, (iii) the ability of the Company to file required financial results in a timely manner, (iv) the Company&#8217;s ability to successfully remediate the material weaknesses in the Company&#8217;s internal control over financial reporting, (v) the potential for delisting, legal proceedings or government investigations or enforcement actions, including those relating to the subject of the Audit Committee (the &#8220;Audit Committee&#8221;) of the Company&#8217;s Board of Directors&#8217; review or inability to finalize financial results in a timely manner, (vi) the Company&#8217;s ability to obtain additional waivers from the Administrative Agent and the lenders under its credit facilities for any continuing or future defaults or events of default, (vii) volatility of the Company&#8217;s securities due to a variety of factors, including the Company&#8217;s inability to implement its business plans or meet or exceed its financial projections and changes, (viii) the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities, (ix) the ability of the Company to implement its strategic initiatives and continue to innovate Obagi Skincare&#8217;s and Milk Makeup&#8217;s existing products and anticipate and respond to market trends and changes in consumer preferences, (x) any shifts in the preferences of consumers as to where and how they shop, and (xi) social, political and economic conditions. These and other risks, assumptions and uncertainties are more fully described in the Risk Factors section of our 2022 20-F (File No. 01-40207), filed with the SEC on January 16, 2024, and in our other documents that we file or furnish with the SEC, which you are encouraged to read.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any current intention, and assumes no duty, to update publicly any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">forward-looking statement after the distribution of this Form 6-K, whether as a result of new information, future events, changes in assumptions or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div id="i8315596ceb614de78b41c9d8055b0f82_7"></div><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EXHIBIT NO.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">DESCRIPTION</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99.1</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="wald_991xnasdaqcomplianced.htm" style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Waldencast plc press release, dated March </a><a href="wald_991xnasdaqcomplianced.htm" style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">25</a><a href="wald_991xnasdaqcomplianced.htm" style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">, 2024</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i8315596ceb614de78b41c9d8055b0f82_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SIGNATURE</font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, Waldencast plc has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Waldencast plc</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Registrant)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58; March 25, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Michel Brousset</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michel Brousset</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Executive Officer and Interim Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>wald_991xnasdaqcomplianced.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2d9f6343401447d5b0cfe70112db1004_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="image.jpg" src="image.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:384px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:700;line-height:120%">Waldencast Regains Compliance with Nasdaq Filing Requirements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">March 25, 2024  &#8211;  White Plains, New York</font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  &#8211;  Waldencast plc, (NASDAQ&#58; WALD) (&#8220;Waldencast&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a global multi-brand beauty and wellness platform, announced that on March 21, 2024 the Company </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">received formal notice from the Nasdaq Hearings Panel (the &#8220;Panel&#8221;) confirming that it has regained compliance with Nasdaq&#8217;s filing requirements, as set forth in Nasdaq Listing Rule 5250(c) (the &#8220;Periodic Filing Rule&#8221;) following the filing of the Company&#8217;s financial results for the interim period ended June 30, 2023 with the U.S. Securities and Exchange Commission.  In line with the applicable Nasdaq Listing Rules in such circumstances, the notice also indicated that Nasdaq had imposed a &#8220;Mandatory Panel Monitor&#8221; as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the compliance determination (March 21, 2024), pursuant to which in the event the Company fails to timely satisfy the Periodic Filing Rule during the one-year monitor period, the Company will not have the opportunity to provide a compliance plan for the Nasdaq Listing Qualifications Staff&#8217;s review&#59; rather, Nasdaq would instead issue a delist determination pursuant to which the Company could request a hearing and stay of the delist determination pending another hearing before the Panel. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Waldencast is proud to have accomplished this significant milestone and looks forward to providing further updates on its fiscal year 2023 performance in connection with the publication of its 2023 20-F.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Statements in this report that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include&#58; the Company&#8217;s timing of filing its 2023 20-F&#59; and any assumptions underlying any of the foregoing. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; and &#8220;will&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements, including, among others&#58; (i) the inability to recognize the anticipated benefits of the business combination with Obagi Skincare and Milk Makeup, (ii) failure by the Company to maintain compliance with Nasdaq&#8217;s Periodic Filing Rule , including during the one-year Nasdaq monitoring period, which may result in the Company&#8217;s securities being delisted from Nasdaq, (iii) the ability of the Company to file required financial results in a timely manner, (iv) the Company&#8217;s ability to successfully remediate the material weaknesses in the Company&#8217;s internal control over financial reporting, (v) the potential for delisting, legal proceedings or government investigations or enforcement actions, including those relating to the subject of the Audit Committee (the &#8220;Audit Committee&#8221;) of the Company&#8217;s Board of Directors&#8217; review or inability to finalize financial results in a timely manner, (vi) the Company&#8217;s ability to obtain additional waivers from the Administrative Agent and the lenders under its credit facilities for any continuing or future defaults or events of default, (vii) volatility of the Company&#8217;s securities due to a variety of factors, including the Company&#8217;s inability to implement its business plans or meet or exceed its financial projections and changes, (viii) the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities, (ix) the ability of the Company to implement its strategic initiatives and continue to innovate Obagi Skincare&#8217;s and Milk Makeup&#8217;s existing products and anticipate and respond to market trends and changes in consumer preferences, (x) any shifts in the preferences of consumers as to where and how they shop, and (xi) social, political and economic conditions. These and other risks, assumptions and uncertainties are more fully described in the Risk Factors section of our 2022 20-F (File No. 01-40207), filed with the SEC on January 16, 2024, and in our other documents that we file or furnish with the SEC, which you are encouraged to read.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this Form 6-K, whether as a result of new information, future events, changes in assumptions or otherwise.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e2dbd4;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">About Waldencast plc</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Founded by Michel Brousset and Hind Sebti, Waldencast&#8217;s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands.  Waldencast&#8217;s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand&#8217;s distinct DNA.  The first step in realizing its vision was the business combination with Obagi Skincare and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform&#59; the expertise in managing global beauty brands at scale&#59; a balanced portfolio to mitigate category fluctuations&#59; asset light efficiency&#59; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit&#58; https&#58;&#47;&#47;ir.waldencast.com&#47;.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Obagi Skincare is an industry-leading, advanced skin care line rooted in research and skin biology, refined with a legacy of 30 years&#8217; experience. First known as leaders in the treatment of hyperpigmentation with the Obagi Nu-Derm&#174; System, Obagi Skincare products are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. More information about Obagi Skincare is available on the brand&#8217;s website, Facebook, Twitter and Instagram pages. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Founded in 2016, Milk Makeup quickly became a cult-favorite among the beauty community for its values of self-expression and inclusion, captured by its signature Live Your Look, its innovative formulas and clean ingredients. The brand creates vegan, cruelty-free, clean formulas from its Milk Makeup HQ in Downtown NYC. Currently, Milk Makeup offers over 300 products through its US website www.MilkMakeup.com, and its retail partners including Sephora in North America, Europe, the Middle East and Australia and Cult Beauty and Selfridges in the UK. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Investors</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ICR </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allison Malkin </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">waldencastir&#64;icrinc.com </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Media</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ICR</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Brittney Fraser&#47;Alecia Pulman</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">waldencast&#64;icrinc.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
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8U>O]%_:/$6Z[@K\)     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
